Faculty Opinions recommendation of Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study.

2020 ◽  
Author(s):  
Mariano Rodriguez ◽  
María E Rodríguez
Keyword(s):  
Growth Factor ◽  
Bone Turnover ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Fibroblast Growth ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Post Hoc Analysis ◽  
Post Hoc

scholarly journals Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study

2018 ◽  
Vol 40 (12) ◽  
pp. 2099-2111 ◽  
Author(s):  
Takashi Shigematsu ◽  
Masafumi Fukagawa ◽  
Keitaro Yokoyama ◽  
Takashi Akiba ◽  
Akifumi Fujii ◽  
...  
Keyword(s):  
Growth Factor ◽  
Bone Turnover ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Fibroblast Growth ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Post Hoc Analysis ◽  
Post Hoc

4.51 LONG-TERM EFFICACY OF LURASIDONE IN ANTIPSYCHOTIC-NAÏVE VERSUS ANTIPSYCHOTIC-EXPOSED ADOLESCENTS WITH SCHIZOPHRENIA: POST-HOC ANALYSIS OF A 2-YEAR, OPEN-LABEL STUDY

2019 ◽  
Vol 58 (10) ◽  
pp. S236
Author(s):  
Christoph U. Correll ◽  
Robert S. Goldman ◽  
Michael Tocco ◽  
Andrei A. Pikalov ◽  
Jay Hsu ◽  
...  
Keyword(s):  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Post Hoc Analysis ◽  
Term Efficacy ◽  
Post Hoc

scholarly journals FP618THE ASSOCIATION OF FIBROBLAST GROWTH FACTOR - 23 AND BONE TURNOVER MARKERS ON HEMODIALYSIS PATIENTS

2018 ◽  
Vol 33 (suppl_1) ◽  
pp. i250-i250
Author(s):  
Ping-Hsun Wu ◽  
Yi-Ting Lin ◽  
Mei-Chuan Kuo ◽  
Yi-Wen Chiu
Keyword(s):  
Growth Factor ◽  
Bone Turnover ◽  
Fibroblast Growth Factor ◽  
Bone Turnover Markers ◽  
Fibroblast Growth Factor 23 ◽  
Hemodialysis Patients ◽  
Fibroblast Growth ◽  
Turnover Markers

scholarly journals Post hoc analysis of a phase 3, multicenter, open‐label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medications

Epilepsia ◽  
2021 ◽  
Author(s):  
William E. Rosenfeld ◽  
Bassel Abou‐Khalil ◽  
Sami Aboumatar ◽  
Perminder Bhatia ◽  
Victor Biton ◽  
...  
Keyword(s):  
Open Label ◽  
Phase 3 ◽  
Open Label Study ◽  
Label Study ◽  
Post Hoc Analysis ◽  
Focal Seizures ◽  
Post Hoc

scholarly journals Safety and Effectiveness of Long-Term Treatment with Lurasidone in Older Adults with Bipolar Depression: Post-Hoc Analysis of a 6-Month, Open-Label Study

2018 ◽  
Vol 26 (2) ◽  
pp. 150-159 ◽  
Author(s):  
Brent P. Forester ◽  
Martha Sajatovic ◽  
Joyce Tsai ◽  
Andrei Pikalov ◽  
Josephine Cucchiaro ◽  
...  
Keyword(s):  
Older Adults ◽  
Bipolar Depression ◽  
Term Treatment ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Post Hoc Analysis ◽  
Long Term Treatment ◽  
Post Hoc

scholarly journals Bone Formation Regulates Circulating Concentrations of Fibroblast Growth Factor 23

Endocrinology ◽  
2009 ◽  
Vol 150 (11) ◽  
pp. 4835-4845 ◽  
Author(s):  
Rana Samadfam ◽  
Christian Richard ◽  
Loan Nguyen-Yamamoto ◽  
Isabel Bolivar ◽  
David Goltzman
Keyword(s):  
Gene Expression ◽  
Growth Factor ◽  
Bone Formation ◽  
Bone Turnover ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Negative Regulator ◽  
Fibroblast Growth ◽  
Osteoblastic Cell Line ◽  
High Calcium

We examined the role of bone remodeling in the regulation of circulating concentrations of FGF23 using mouse models manifesting differing degrees of coupled and uncoupled bone turnover. Administration of the antiresorptive agent osteoprotegerin produced a profound reduction in bone resorption and formation in male and oophorectomized female mice, accompanied by an increase in serum levels of fibroblast growth factor 23 (FGF23) and a reduction in circulating 1,25-dihydroxyvitamin D [1,25(OH)2D]. In contrast, exogenous PTH(1-34) administration increased bone turnover and reduced circulating FGF23. In 1,25(OH)2D-deficient, 25-hydroxyvitamin D 1α-hydroxylase null mice on a high-calcium diet, endogenous PTH was elevated, bone formation but not resorption was increased, and serum FGF23 was virtually undetectable; on a rescue diet, serum calcium was normalized, PTH levels were reduced, bone formation was reduced, and serum FGF23 levels increased. After PTH treatment of wild-type mice, gene expression of dentin matrix protein 1 (DMP1) in bone was increased, whereas gene expression of FGF23 was reduced. In vitro studies in the osteoblastic cell line UMR-106 showed that externally added DMP1 could inhibit FGF23 gene expression and production stimulated by 1,25(OH)2D3. The results show that osteoblastic bone formation is a potent modulator of FGF23 production and release into the circulation, suggest that the biological consequences on mineral homeostasis of circulating FGF23 may also be dependent on the prevailing rate of bone turnover, and provide evidence that DMP1 may be a direct negative regulator of FGF23 production in osteoblastic cells.

scholarly journals A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study

2013 ◽  
Vol 28 (9) ◽  
pp. 2383-2392 ◽  
Author(s):  
Adrian Covic ◽  
Jutta Passlick-Deetjen ◽  
Miroslaw Kroczak ◽  
Beatrix Büschges-Seraphin ◽  
Adrian Ghenu ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Bone Markers ◽  
Fibroblast Growth Factor 23 ◽  
Randomized Study ◽  
Magnesium Carbonate ◽  
Calcium Acetate ◽  
Fibroblast Growth ◽  
Sevelamer Hydrochloride ◽  
Post Hoc
Sign in / Sign up

Export Citation Format

Share Document